Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, doxorubicin was added to the complementary list of the EML for use in treatment protocols for metastatic breast cancer. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic breast cancer is attached.